Aromatase inhibitor treatment for breast cancer: short-term effect on bone health

Basit Öğe Kaydı
dc.authoridAsik, mehmet/0000-0002-0716-0221
dc.contributor.authorErbag, Gokhan
dc.contributor.authorUygun, Kazim
dc.contributor.authorBinnetoglu, Emine
dc.contributor.authorKorkmaz, Ayse Nurdan
dc.contributor.authorAsik, Mehmet
dc.contributor.authorSen, Hacer
dc.contributor.authorGunes, Fahri
dc.date.accessioned2025-01-27T20:45:36Z
dc.date.available2025-01-27T20:45:36Z
dc.date.issued2015
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAim of this study was to examine the effects of aromatase inhibitors (AIs), which are used in every phase of breast cancer treatment, on the bone mineral density (BMD) of patients with early-stage breast cancer. Material and methods: Menopausal female patients who were diagnosed with stages 1-3 breast cancer and who were planned for anastrazole or letrozole as adjuvant therapy were examined. After the patients' BMD was measured, 45 patients without osteoporosis were included in the study. Six months after AI therapy started, the patients' BMD was measured again. Results: In this study, we tried to show that there was a statistical difference in the BMD of 45 patients before and 6 months after treatment. Among all measurements (femur and lumbar T-scores), the femur Z-score (p = 0.52) was the only score that was not statistically significant. Statistical significance (p < 0.01) was detected in comparative analysis of the other measurements. According to this analysis, a significant loss of BMD was seen even in the first six months after AI treatment was introduced. Conclusions: Female patients with breast cancer are at higher risk for bone loss and fractures than healthy women. In this study, we showed the negative effects on BMD of aromatase inhibitor therapy, one of the main contributions to osteoporosis in women with breast cancer. This study is the first to quantify the short-term effect of AI treatment on BMD in postmenopausal women with breast cancer.
dc.identifier.doi10.5114/wo.2014.45305
dc.identifier.endpage377
dc.identifier.issn1428-2526
dc.identifier.issn1897-4309
dc.identifier.issue5
dc.identifier.pmid26793021
dc.identifier.scopus2-s2.0-84955079157
dc.identifier.scopusqualityQ2
dc.identifier.startpage374
dc.identifier.urihttps://doi.org/10.5114/wo.2014.45305
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24651
dc.identifier.volume19
dc.identifier.wosWOS:000422089600006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTermedia Publishing House Ltd
dc.relation.ispartofWspolczesna Onkologia-Contemporary Oncology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectaromatase inhibitor
dc.subjectbreast cancer
dc.subjectbone mineral density
dc.subjectosteoporosis
dc.titleAromatase inhibitor treatment for breast cancer: short-term effect on bone health
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu